BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D’Arminio Monforte A, Friis-Møller N. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426. [PMID: 18387667 DOI: 10.1016/s0140-6736(08)60423-7] [Cited by in Crossref: 585] [Cited by in F6Publishing: 230] [Article Influence: 41.8] [Reference Citation Analysis]
Number Citing Articles
1 Feinstein MJ, Bogorodskaya M, Bloomfield GS, Vedanthan R, Siedner MJ, Kwan GF, Longenecker CT. Cardiovascular Complications of HIV in Endemic Countries. Curr Cardiol Rep 2016;18:113. [PMID: 27730474 DOI: 10.1007/s11886-016-0794-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
2 Seecheran VK, Giddings SL, Seecheran NA. Acute coronary syndromes in patients with HIV. Coron Artery Dis 2017;28:166-72. [PMID: 27845996 DOI: 10.1097/MCA.0000000000000450] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
3 Armon C, Lichtenstein K. The associations among coping, nadir CD4+ T-cell count, and non-HIV-related variables with health-related quality of life among an ambulatory HIV-positive patient population. Qual Life Res 2012;21:993-1003. [PMID: 21938643 DOI: 10.1007/s11136-011-0017-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
4 Schoepf IC, Buechel RR, Kovari H, Hammoud DA, Tarr PE. Subclinical Atherosclerosis Imaging in People Living with HIV. J Clin Med 2019;8:E1125. [PMID: 31362391 DOI: 10.3390/jcm8081125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
5 Maggiolo F, Gulminetti R, Pagnucco L, Digaetano M, Benatti S, Valenti D, Callegaro A, Ripamonti D, Mussini C. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis 2017;17:215. [PMID: 28302065 DOI: 10.1186/s12879-017-2311-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
6 Conklin J, Pineda LJ. HIV update: Impact on chronic diseases. Pharmacy Today 2017;23:57-69. [DOI: 10.1016/j.ptdy.2017.07.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
7 Dharan NJ, Radovich T, Che S, Petoumenos K, Juneja P, Law M, Huang R, McManus H, Polizzotto MN, Guy R, Cronin P, Cooper DA, Gray RT. Comorbidity Medications Are Dispensed to More People Receiving Antiretroviral Therapy for HIV Compared with the General Population in Australia. AIDS Res Hum Retroviruses 2020;36:291-6. [PMID: 31838857 DOI: 10.1089/AID.2019.0117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, Pillay D, Rockstroh J, Geretti AM. When and how to use maraviroc in HIV-infected patients. AIDS 2009;23:2377-85. [PMID: 19834318 DOI: 10.1097/QAD.0b013e328332d32d] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
9 Zaaqoq AM, Khasawneh FA, Smalligan RD. Cardiovascular Complications of HIV-Associated Immune Dysfunction. Cardiol Res Pract 2015;2015:302638. [PMID: 25648075 DOI: 10.1155/2015/302638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
10 Samaras K. HIV, insulin resistance and cardiovascular disease. Curr Cardio Risk Rep 2009;3:59-64. [DOI: 10.1007/s12170-009-0010-2] [Reference Citation Analysis]
11 Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-33. [PMID: 18784465 DOI: 10.1097/QAD.0b013e3283103ce6] [Cited by in Crossref: 114] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
12 Biron A, Bobin-Dubigeon C, Volteau C, Piroth L, Perré P, Leport C, Prazuck T, Jovelin T, Billard M, Sébille V, Bard JM, Raffi F, Biron C. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy. AIDS Res Hum Retroviruses 2012;28:1672-8. [PMID: 22731114 DOI: 10.1089/AID.2012.0048] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
13 de Gaetano Donati K, Cauda R, Iacoviello L. HIV Infection, Antiretroviral Therapy and Cardiovascular Risk. Mediterr J Hematol Infect Dis 2010;2:e2010034. [PMID: 21776340 DOI: 10.4084/MJHID.2010.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
14 Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, Ganz P, Hsue PY. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010;24:1897-905. [PMID: 20543654 DOI: 10.1097/QAD.0b013e32833bee44] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
15 Boyd MA, Mocroft A, Ryom L, Monforte AD, Sabin C, El-Sadr WM, Hatleberg CI, De Wit S, Weber R, Fontas E, Phillips A, Bonnet F, Reiss P, Lundgren J, Law M. Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Med 2017;14:e1002424. [PMID: 29112958 DOI: 10.1371/journal.pmed.1002424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
16 . Cardiovascular computed tomography and HIV: The evolving role of imaging biomarkers in enhanced risk prediction. Imaging 2021;13:106-18. [DOI: 10.1556/1647.2021.00025] [Reference Citation Analysis]
17 Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One 2013;8:e59551. [PMID: 23555704 DOI: 10.1371/journal.pone.0059551] [Cited by in Crossref: 133] [Cited by in F6Publishing: 131] [Article Influence: 14.8] [Reference Citation Analysis]
18 Merlini E, Luzi K, Suardi E, Barassi A, Cerrone M, Martínez JS, Bai F, D'Eril GV, Monforte AD, Marchetti G. T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One 2012;7:e46073. [PMID: 23029393 DOI: 10.1371/journal.pone.0046073] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
19 Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab 2008;93:2937-45. [PMID: 18685115 DOI: 10.1210/jc.2008-1019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
20 Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23:1547-56. [PMID: 19542866 DOI: 10.1097/QAD.0b013e32832cbcc2] [Cited by in Crossref: 163] [Cited by in F6Publishing: 77] [Article Influence: 12.5] [Reference Citation Analysis]
21 Stradling C, Thomas GN, Hemming K, Frost G, Garcia-Perez I, Redwood S, Taheri S. Randomised controlled pilot study to assess the feasibility of a Mediterranean Portfolio dietary intervention for cardiovascular risk reduction in HIV dyslipidaemia: a study protocol. BMJ Open 2016;6:e010821. [PMID: 26857107 DOI: 10.1136/bmjopen-2015-010821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
22 Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE; AIDS Clinical Trials Group (ACTG) 372A Study Team. A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen. HIV Clinical Trials 2015;11:312-24. [DOI: 10.1310/hct1105-312] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
23 Gallant JE, Thompson M, DeJesus E, Voskuhl GW, Wei X, Zhang H, White K, Cheng A, Quirk E, Martin H. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults. J Acquir Immune Defic Syndr 2017;75:61-6. [PMID: 28196003 DOI: 10.1097/QAI.0000000000001306] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 8.4] [Reference Citation Analysis]
24 Hileman CO, Wohl DA, Tisch DJ, Debanne SM, McComsey GA. Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. AIDS Res Hum Retroviruses 2012;28:1561-4. [PMID: 22463776 DOI: 10.1089/AID.2012.0034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
25 Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, Fontas E, Mocroft A, de Wit S, Smith C, Dabis F, d'Arminio Monforte A, El-Sadr W, Lundgren JD; D:A:D Study Group. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med 2016;14:61. [PMID: 27036962 DOI: 10.1186/s12916-016-0588-4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
26 Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, Natarajan V, Rehm C, Hadigan C, Sereti I. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010;24:1509-17. [PMID: 20505494 DOI: 10.1097/QAD.0b013e32833ad914] [Cited by in Crossref: 139] [Cited by in F6Publishing: 113] [Article Influence: 11.6] [Reference Citation Analysis]
27 Akanbi MO, Scarsi KK, Taiwo B, Murphy RL. Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. Expert Opin Pharmacother 2012;13:65-79. [PMID: 22149368 DOI: 10.1517/14656566.2012.642865] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
28 Baker JV. Chronic HIV disease and activation of the coagulation system. Thromb Res 2013;132:495-9. [PMID: 24034985 DOI: 10.1016/j.thromres.2013.08.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
29 Hammond E, McKinnon E, Mallal S, Nolan D. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS 2008;22:2540-3. [PMID: 19005279 DOI: 10.1097/QAD.0b013e328319807f] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
30 O'Halloran JA, Dunne E, Tinago W, Denieffe S, Kenny D, Mallon PWG. Switching from abacavir to tenofovir disoproxil fumarate is associated with rises in soluble glycoprotein VI, suggesting changes in platelet-collagen interactions. AIDS 2018;32:861-6. [PMID: 29438200 DOI: 10.1097/QAD.0000000000001783] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.8] [Reference Citation Analysis]
31 Lai S, Bartlett J, Lai H, Moore R, Cofrancesco J Jr, Pannu H, Tong W, Meng W, Sun H, Fishman EK. Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection. AIDS Patient Care STDS 2009;23:815-24. [PMID: 19803679 DOI: 10.1089/apc.2009.0048] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
32 Barbarino JM, Kroetz DL, Altman RB, Klein TE. PharmGKB summary: abacavir pathway. Pharmacogenet Genomics 2014;24:276-82. [PMID: 24625462 DOI: 10.1097/FPC.0000000000000040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
33 Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012;91:734-8. [PMID: 22378157 DOI: 10.1038/clpt.2011.355] [Cited by in Crossref: 131] [Cited by in F6Publishing: 103] [Article Influence: 13.1] [Reference Citation Analysis]
34 Pathai S, Weiss HA, Lawn SD, Peto T, D'Costa LM, Cook C, Wong TY, Gilbert CE. Retinal arterioles narrow with increasing duration of anti-retroviral therapy in HIV infection: a novel estimator of vascular risk in HIV? PLoS One 2012;7:e51405. [PMID: 23251521 DOI: 10.1371/journal.pone.0051405] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
35 Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 2011;25:2243-8. [PMID: 21941165 DOI: 10.1097/QAD.0b013e32834d3cc3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
36 Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE; AIDS Clinical Trials Group (ACTG) 372A Study Team. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials 2010;11:312-24. [PMID: 21239359 DOI: 10.1310/hct1106-312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
37 Trevillyan JM, Arthur JF, Jing J, Andrews RK, Gardiner EE, Hoy JF. Effects of abacavir administration on structural and functional markers of platelet activation. AIDS 2015;29:2309-13. [PMID: 26544702 DOI: 10.1097/QAD.0000000000000848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
38 Wilkinson JD, Williams PL, Leister E, Zeldow B, Shearer WT, Colan SD, Siberry GK, Dooley LB, Scott GB, Rich KC, Lipshultz SE; Pediatric HIVAIDS Cohort Study (PHACS). Cardiac biomarkers in HIV-exposed uninfected children. AIDS 2013;27:1099-108. [PMID: 23211773 DOI: 10.1097/QAD.0b013e32835cf21c] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
39 Bratt G, Brännström J, Missalidis C, Nyström T. Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors. PLoS One 2021;16:e0254079. [PMID: 34191847 DOI: 10.1371/journal.pone.0254079] [Reference Citation Analysis]
40 Palella FJ Jr, Gange SJ, Benning L, Jacobson L, Kaplan RC, Landay AL, Tracy RP, Elion R. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010;24:1657-65. [PMID: 20588104 DOI: 10.1097/QAD.0b013e3283389dfa] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
41 Lin HL, D'Agostino J, Kenaan C, Calinski D, Hollenberg PF. The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir. Drug Metab Dispos 2013;41:1813-24. [PMID: 23886699 DOI: 10.1124/dmd.113.053108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
42 Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. AIDS 2017;31 Suppl 2:S173-84. [PMID: 28471948 DOI: 10.1097/QAD.0000000000001401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
43 Durand M, Chartrand-Lefebvre C, Baril JG, Trottier S, Trottier B, Harris M, Walmsley S, Conway B, Wong A, Routy JP, Kovacs C, MacPherson PA, Monteith KM, Mansour S, Thanassoulis G, Abrahamowicz M, Zhu Z, Tsoukas C, Ancuta P, Bernard N, Tremblay CL; investigators of the Canadian HIV and Aging Cohort Study. The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol. BMC Infect Dis 2017;17:611. [PMID: 28893184 DOI: 10.1186/s12879-017-2692-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
44 Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y. Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan. Pharmacoepidemiol Drug Saf 2014;23:372-81. [PMID: 24590575 DOI: 10.1002/pds.3588] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
45 Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol 2011;6:223-48. [PMID: 21034222 DOI: 10.1146/annurev-pathol-011110-130254] [Cited by in Crossref: 234] [Cited by in F6Publishing: 189] [Article Influence: 19.5] [Reference Citation Analysis]
46 Kearney F, Moore AR, Donegan CF, Lambert J. The ageing of HIV: implications for geriatric medicine. Age Ageing 2010;39:536-41. [PMID: 20685813 DOI: 10.1093/ageing/afq083] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
47 Diaz CM, Segura ER, Luz PM, Clark JL, Ribeiro SR, De Boni R, Eksterman L, Moreira R, Currier JS, Veloso VG, Grinsztejn B, Lake JE. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. BMC Infect Dis 2016;16:376. [PMID: 27503230 DOI: 10.1186/s12879-016-1735-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
48 Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454. [PMID: 22970224 DOI: 10.1371/journal.pone.0044454] [Cited by in Crossref: 352] [Cited by in F6Publishing: 356] [Article Influence: 35.2] [Reference Citation Analysis]
49 Oni T, Unwin N. Why the communicable/non-communicable disease dichotomy is problematic for public health control strategies: implications of multimorbidity for health systems in an era of health transition. Int Health 2015;7:390-9. [PMID: 26103981 DOI: 10.1093/inthealth/ihv040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
50 Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J Antimicrob Chemother 2011;66:265-72. [PMID: 21196489 DOI: 10.1093/jac/dkq458] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
51 Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ; AIDS Clinical Trials Group A5095 Study Team. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses 2011;27:461-8. [PMID: 20863238 DOI: 10.1089/aid.2010.0154] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
52 Frades I, Readhead B, Amadori L, Koplev S, Talukdar HA, Crane HM, Crane PK, Kovacic JC, Dudley JT, Giannarelli C, Björkegren JLM, Peter I. Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy. Circ Genom Precis Med 2019;12:e002390. [PMID: 31059280 DOI: 10.1161/CIRCGEN.118.002390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Bhatia NS, Chow FC. Neurologic Complications in Treated HIV-1 Infection. Curr Neurol Neurosci Rep 2016;16:62. [PMID: 27170369 DOI: 10.1007/s11910-016-0666-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
54 Gianotti N, Cozzi-Lepri A, Antinori A, Castagna A, De Luca A, Celesia BM, Galli M, Mussini C, Pinnetti C, Spagnuolo V, d'Arminio Monforte A, Ceccherini-Silberstein F, Andreoni M; Icona Foundation Study and mono-PI/r database Study Cohorts. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One 2017;12:e0171611. [PMID: 28192453 DOI: 10.1371/journal.pone.0171611] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
55 Rizzardini G, Gori A, Miralles C, Olalla J, Molina JM, Raffi F, Kumar P, Antinori A, Ramgopal M, Stellbrink HJ, Das M, Chu H, Ram R, Garner W, Shao Y, Chuck SK, Piontkowsky D, Haubrich RH. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. AIDS 2019;33:1583-93. [PMID: 31305329 DOI: 10.1097/QAD.0000000000002244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 van Wijk JP, Cabezas MC. Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med 2012;2012:201027. [PMID: 21876813 DOI: 10.1155/2012/201027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
57 Dharan NJ, Radovich T, Che S, Petoumenos K, Juneja P, Law M, Huang R, McManus H, Polizzotto MN, Guy R, Cronin P, Cooper DA, Gray RT. HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme. BMC Public Health 2019;19:13. [PMID: 30606134 DOI: 10.1186/s12889-018-6325-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
58 Soriano V, Geretti AM, Perno CF, Fätkenheuer G, Pillay D, Reynes J, Tambussi G, Calvez V, Alcamí J, Rockstroh J. Optimal use of maraviroc in clinical practice. AIDS 2008;22:2231-40. [PMID: 18981762 DOI: 10.1097/QAD.0b013e3283136d95] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
59 Askgaard G, Kristoffersen US, Mehlsen J, Kronborg G, Kjaer A, Lebech AM. Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol. PLoS One 2011;6:e20196. [PMID: 21655281 DOI: 10.1371/journal.pone.0020196] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
60 Himmel DM, Arnold E. Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV. Pharmaceuticals (Basel) 2020;13:E122. [PMID: 32545407 DOI: 10.3390/ph13060122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
61 Urata Y, Paintsil E, Cheng YC, Matsuda T, Sevinsky H, Hawthorne D, Bertz R, Hanna GJ, Grasela D, Hwang C. Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects. J Clin Pharmacol 2014;54:657-64. [PMID: 24374821 DOI: 10.1002/jcph.252] [Reference Citation Analysis]
62 Sasson SC, Kelleher AD. Site-specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV-1? Clin Transl Immunology 2014;3:e19. [PMID: 25505967 DOI: 10.1038/cti.2014.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
63 Hearps AC, Martin GE, Rajasuriar R, Crowe SM. Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep 2014;11:20-34. [PMID: 24414166 DOI: 10.1007/s11904-013-0190-8] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
64 McGettrick P, Barco EA, Mallon PWG. Ageing with HIV. Healthcare (Basel) 2018;6:E17. [PMID: 29443936 DOI: 10.3390/healthcare6010017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
65 Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26-39. [PMID: 23963694 DOI: 10.1007/s13181-013-0325-8] [Cited by in Crossref: 175] [Cited by in F6Publishing: 161] [Article Influence: 21.9] [Reference Citation Analysis]
66 Gupta RK, Van de Vijver DA, Manicklal S, Wainberg MA. Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology 2013;10:82. [PMID: 23902855 DOI: 10.1186/1742-4690-10-82] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
67 Shahmanesh M, Schultze A, Burns F, Kirk O, Lundgren J, Mussini C, Pedersen C, De Wit S, Kutsyna G, Mocroft A; EuroSIDA in EuroCOORD. The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS 2016;30:2505-18. [PMID: 27456984 DOI: 10.1097/QAD.0000000000001207] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
68 Sadouni M, Durand M, Boldeanu I, Danieli C, Bodson-Clermont P, Mansour S, Baril JG, Trottier B, Tremblay C, Chartrand-Lefebvre C; investigators of the Canadian HIV and Aging Cohort Study. Association of epicardial fat with noncalcified coronary plaque volume and with low attenuation plaque in people with HIV. AIDS 2021;35:1575-84. [PMID: 33831908 DOI: 10.1097/QAD.0000000000002911] [Reference Citation Analysis]
69 Gilliam BL, Riedel DJ, Redfield RR. Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med 2011;9 Suppl 1:S9. [PMID: 21284908 DOI: 10.1186/1479-5876-9-S1-S9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
70 Raj SR, Stein CM, Saavedra PJ, Roden DM. Cardiovascular effects of noncardiovascular drugs. Circulation 2009;120:1123-32. [PMID: 19770411 DOI: 10.1161/CIRCULATIONAHA.107.728576] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
71 Berry SA, Fleishman JA, Moore RD, Gebo KA; HIV Research Network. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr 2012;59:368-75. [PMID: 22240460 DOI: 10.1097/QAI.0b013e318246b862] [Cited by in Crossref: 82] [Cited by in F6Publishing: 57] [Article Influence: 8.2] [Reference Citation Analysis]
72 Nayak G, Ferguson M, Tribble DR, Porter CK, Rapena R, Marchicelli M, Decker CF. Cardiac diastolic dysfunction is prevalent in HIV-infected patients. AIDS Patient Care STDS 2009;23:231-8. [PMID: 19281430 DOI: 10.1089/apc.2008.0142] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
73 Stellbrink HJ, Baldus S, Behrens G, Bogner JR, Harrer T, Hoffmann C, van Lunzen J, Münch J, Racz P, Scheller C, Stoll M, Tenner-Racz K, Rockstroh J. HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008. Eur J Med Res 2010;15:1-12. [PMID: 20159665 DOI: 10.1186/2047-783x-15-1-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
74 Hirschel B, Flanigan T. Is it smart to continue to study treatment interruptions? AIDS 2009;23:757-9. [PMID: 19307943 DOI: 10.1097/QAD.0b013e328321b791] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
75 Sinn K, Richardson R, Carr A. Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk. AIDS 2010;24:2403-5. [PMID: 20647907 DOI: 10.1097/QAD.0b013e32833d568f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Lesko CR, Moore RD, Tong W, Lau B. Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014. AIDS 2016;30:1447-55. [PMID: 26990627 DOI: 10.1097/QAD.0000000000001087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
77 El Khoury L, Célerse F, Lagardère L, Jolly LH, Derat E, Hobaika Z, Maroun RG, Ren P, Bouaziz S, Gresh N, Piquemal JP. Reconciling NMR Structures of the HIV-1 Nucleocapsid Protein NCp7 Using Extensive Polarizable Force Field Free-Energy Simulations. J Chem Theory Comput 2020;16:2013-20. [PMID: 32178519 DOI: 10.1021/acs.jctc.9b01204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
78 Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol. 2014;11:728-741. [PMID: 25331088 DOI: 10.1038/nrcardio.2014.167] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
79 Lee FJ. Measurement of soluble glycoprotein VI in studies of abacavir-based therapy: concerns about test precision. AIDS 2018;32:2263-4. [PMID: 30212406 DOI: 10.1097/QAD.0000000000001944] [Reference Citation Analysis]
80 Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Mller N, Mercie P, Lundgren JD, Sabin C. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS 2011;25:1497-504. [PMID: 21633288 DOI: 10.1097/QAD.0b013e32834917c6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
81 Pulido F, Arribas JR. Noninferiority and lopinavir/ritonavir monotherapy trials. AIDS 2008;22:1696-7. [PMID: 18670240 DOI: 10.1097/QAD.0b013e32830a98ac] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
82 Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ Jr; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 2018;78:62-72. [PMID: 29419568 DOI: 10.1097/QAI.0000000000001642] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 10.7] [Reference Citation Analysis]
83 Echeverría P, Domingo P, Llibre JM, Gutierrez M, Mateo G, Puig J, Bonjoch A, Pérez-Alvarez N, Sirera G, Clotet B, Negredo E. Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients. Biomed Res Int 2014;2014:823058. [PMID: 25170515 DOI: 10.1155/2014/823058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
84 Phan BAP, Ma Y, Scherzer R, Deeks SG, Hsue PY. Association between statin use, atherosclerosis, and mortality in HIV-infected adults. PLoS One 2020;15:e0232636. [PMID: 32353062 DOI: 10.1371/journal.pone.0232636] [Reference Citation Analysis]
85 Anderson AM, Lennox JL. Antiretroviral therapy: when to start and which drugs to use. Curr Infect Dis Rep 2008;10:332-9. [PMID: 18765108 DOI: 10.1007/s11908-008-0053-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
86 Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155. [PMID: 21090961 DOI: 10.1146/annurev-med-042909-093756] [Cited by in Crossref: 790] [Cited by in F6Publishing: 778] [Article Influence: 71.8] [Reference Citation Analysis]
87 Dorjee K, Baxi SM, Reingold AL, Hubbard A. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis 2017;17:708. [PMID: 29078761 DOI: 10.1186/s12879-017-2808-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
88 Gebo KA. Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging health 2008;4:615-27. [PMID: 19915688 DOI: 10.2217/1745509X.4.6.615] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
89 Rasmussen TA, Tolstrup M, Melchjorsen J, Frederiksen CA, Nielsen US, Langdahl BL, Østergaard L, Laursen AL. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis 2011;11:267. [PMID: 21970555 DOI: 10.1186/1471-2334-11-267] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
90 Triant VA, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, Miller V, Strobos J. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin Infect Dis 2012;54:408-13. [PMID: 22095570 DOI: 10.1093/cid/cir829] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
91 Şahin EA, Mavi D, Kara E, Sönmezer MÇ, İnkaya AÇ, Ünal S. Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years. Postgrad Med 2022;:1-6. [PMID: 35671079 DOI: 10.1080/00325481.2022.2085931] [Reference Citation Analysis]
92 Bifulco M, Gazzerro P. The right to care and the expectations of society--controversial stem cell therapy in Italy. EMBO Rep 2013;14:578. [PMID: 23732540 DOI: 10.1038/embor.2013.71] [Reference Citation Analysis]
93 Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 2014;28:131-45. [PMID: 24362768 DOI: 10.1007/s40263-013-0132-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 11.9] [Reference Citation Analysis]
94 Martin-Iguacel R, Llibre JM, Friis-Moller N. Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now? Curr HIV/AIDS Rep 2015;12:375-87. [PMID: 26423407 DOI: 10.1007/s11904-015-0284-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
95 Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, Kimaiyo S. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. PLoS One. 2011;6:e22288. [PMID: 21779407 DOI: 10.1371/journal.pone.0022288] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
96 Strategies for Management of Anti-Retroviral Therapy/INSIGHT., DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-24. [PMID: 18753925 DOI: 10.1097/QAD.0b013e32830fe35e] [Cited by in Crossref: 239] [Cited by in F6Publishing: 108] [Article Influence: 17.1] [Reference Citation Analysis]
97 Chastain DB, Henderson H, Stover KR. Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J 2015;9:23-37. [PMID: 25866592 DOI: 10.2174/1874613601509010023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
98 Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009;50:54-64. [PMID: 19295335 DOI: 10.1097/QAI.0b013e31818ceaa4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
99 Siedner MJ. Aging, Health, and Quality of Life for Older People Living With HIV in Sub-Saharan Africa: A Review and Proposed Conceptual Framework. J Aging Health 2019;31:109-38. [PMID: 28831864 DOI: 10.1177/0898264317724549] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
100 Lawal IO, Ankrah AO, Stoltz AC, Sathekge MM. Radionuclide imaging of inflammation in atherosclerotic vascular disease among people living with HIV infection: current practice and future perspective. Eur J Hybrid Imaging 2019;3:5. [PMID: 34191183 DOI: 10.1186/s41824-019-0053-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
101 Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr 2012;60:351-8. [PMID: 22580566 DOI: 10.1097/QAI.0b013e31825c7f24] [Cited by in Crossref: 195] [Cited by in F6Publishing: 128] [Article Influence: 19.5] [Reference Citation Analysis]
102 Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation 2019;140:e98-e124. [PMID: 31154814 DOI: 10.1161/CIR.0000000000000695] [Cited by in Crossref: 123] [Cited by in F6Publishing: 66] [Article Influence: 41.0] [Reference Citation Analysis]
103 Satchell CS, Cotter AG, O'Connor EF, Peace AJ, Tedesco AF, Clare A, Lambert JS, Sheehan GJ, Kenny D, Mallon PW. Platelet function and HIV: a case-control study. AIDS 2010;24:649-57. [PMID: 20177361 DOI: 10.1097/QAD.0b013e328336098c] [Cited by in Crossref: 54] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
104 Alvarez A, Orden S, Andújar I, Collado-Diaz V, Núñez-Delgado S, Galindo MJ, Estrada V, Apostolova N, Esplugues JV. Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. AIDS 2017;31:1781-95. [PMID: 28537935 DOI: 10.1097/QAD.0000000000001547] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 6.2] [Reference Citation Analysis]
105 Ogunmola OJ, Oladosu OY, Olamoyegun AM. Association of hypertension and obesity with HIV and antiretroviral therapy in a rural tertiary health center in Nigeria: a cross-sectional cohort study. Vasc Health Risk Manag 2014;10:129-37. [PMID: 24672244 DOI: 10.2147/VHRM.S58449] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
106 Kim PS, Woods C, Dutcher L, Georgoff P, Rosenberg A, Mican JA, Kopp JB, Smith MA, Hadigan C. Increased prevalence of albuminuria in HIV-infected adults with diabetes. PLoS One 2011;6:e24610. [PMID: 21931772 DOI: 10.1371/journal.pone.0024610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
107 Kelesidis T, Currier JS. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Endocrinol Metab Clin North Am 2014;43:665-84. [PMID: 25169560 DOI: 10.1016/j.ecl.2014.06.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
108 Sivasubramanian G, Frempong-Manso E, Macarthur RD. Abacavir/lamivudine combination in the treatment of HIV: a review. Ther Clin Risk Manag 2010;6:83-94. [PMID: 20234788 DOI: 10.2147/tcrm.s1657] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
109 Krikke M, Tesselaar K, Arends JE, Drylewicz J, Otto SA, van Lelyveld SF, Visseren FJ, Hoepelman AI. Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study. Infect Dis Ther 2016;5:389-404. [PMID: 27300170 DOI: 10.1007/s40121-016-0115-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
110 Spaziante M, Taliani G, Marchetti G, Tavelli A, Lichtner M, Cingolani A, Cicalini S, Biliotti E, Girardi E, Antinori A, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses 2021;13:1402. [PMID: 34372608 DOI: 10.3390/v13071402] [Reference Citation Analysis]
111 Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte Ad, Pradier C, Thiebaut R, Law M, Rickenbach M, De Wit S, Lundgren JD, Friis-Møller N. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2009;32:474-80. [PMID: 19056612 DOI: 10.2337/dc08-1394] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
112 Adetokunboh OO, Schoonees A, Balogun TA, Wiysonge CS. Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis. BMC Infect Dis 2015;15:469. [PMID: 26502899 DOI: 10.1186/s12879-015-1183-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
113 De Luca A, de Gaetano Donati K, Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A, Sighinolfi L, Giacometti A, Capobianchi MR, D'Avino A, Iacoviello L, Cauda R, D'Arminio Monforte A. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis 2013;13:414. [PMID: 24004495 DOI: 10.1186/1471-2334-13-414] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
114 Möhlenkamp S, Reinsch N, Erbel R, Neumann T. Coronary risk assessment in patients with HIV infection: why bother? Int J Cardiovasc Imaging 2012;28:989-92. [PMID: 21870138 DOI: 10.1007/s10554-011-9940-0] [Reference Citation Analysis]
115 Ngatchou W, Lemogoum D, Ndobo P, Yagnigni E, Tiogou E, Nga E, Kouanfack C, van de Borne P, Hermans MP. Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon. Vasc Health Risk Manag 2013;9:509-16. [PMID: 24043942 DOI: 10.2147/VHRM.S42350] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
116 Aragonès G, Pardo-Reche P, Fernández-Sender L, Rull A, Beltrán-Debón R, Rodríguez-Gallego E, Camps J, Joven J, Alonso-Villaverde C. The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients. Mediators Inflamm 2012;2012:372305. [PMID: 22645407 DOI: 10.1155/2012/372305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010;85:1-18. [PMID: 20018391 DOI: 10.1016/j.antiviral.2009.10.002] [Cited by in Crossref: 280] [Cited by in F6Publishing: 243] [Article Influence: 21.5] [Reference Citation Analysis]
118 Cope R, Berkowitz L, Arcebido R, Yeh JY, Trustman N, Cha A. Evaluating the Effects of an Interdisciplinary Practice Model with Pharmacist Collaboration on HIV Patient Co-Morbidities. AIDS Patient Care STDS 2015;29:445-53. [PMID: 26125093 DOI: 10.1089/apc.2015.0018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
119 Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van’t Wout AB, Lubomirov R, Colombo S, Martinez R. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis. 2013;57:112-121. [PMID: 23532479 DOI: 10.1093/cid/cit196] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
120 Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Clin Pract Cardiovasc Med 2009;6:120-7. [PMID: 19104517 DOI: 10.1038/ncpcardio1437] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
121 Jong E, Meijers JC, van Gorp EC, Spek CA, Mulder JW. Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther 2010;7:9. [PMID: 20398387 DOI: 10.1186/1742-6405-7-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
122 Fichtenbaum CJ. Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep 2011;13:94-101. [PMID: 21308460 DOI: 10.1007/s11908-010-0153-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
123 Boger MS, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, Hulgan T. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr 2009;52:480-7. [PMID: 19911471 DOI: 10.1097/qai.0b013e3181b939e5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
124 Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y. Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan. Pharmacoepidemiol Drug Saf 2014;23:361-71. [PMID: 24585486 DOI: 10.1002/pds.3589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
125 Matza LS, Chung KC, Kim KJ, Paulus TM, Davies EW, Stewart KD, McComsey GA, Fordyce MW. Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. Qual Life Res 2017;26:1785-98. [PMID: 28341926 DOI: 10.1007/s11136-017-1519-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
126 Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, Li XD, Dotterweich W, Pollard RB, Asmuth DM, Berglund L. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol 2013;33:387-92. [PMID: 23202367 DOI: 10.1161/ATVBAHA.112.300125] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
127 Negredo E, Back D, Blanco JR, Blanco J, Erlandson KM, Garolera M, Guaraldi G, Mallon P, Moltó J, Serra JA, Clotet B. Aging in HIV-Infected Subjects: A New Scenario and a New View. Biomed Res Int 2017;2017:5897298. [PMID: 29430462 DOI: 10.1155/2017/5897298] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
128 Grabovac I, Veronese N, Stefanac S, Haider S, Jackson SE, Koyanagi A, Meilinger M, Stubbs B, Firth J, Soysal P, Di Gennaro F, Demurtas J, McDermott DT, Abbs AD, Yang L, Smith L. Human Immunodeficiency Virus Infection and Diverse Physical Health Outcomes: An Umbrella Review of Meta-analyses of Observational Studies. Clin Infect Dis 2020;70:1809-15. [PMID: 31401650 DOI: 10.1093/cid/ciz539] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
129 Singer EJ, Valdes-Sueiras M, Commins DL, Yong W, Carlson M. HIV stroke risk: evidence and implications. Ther Adv Chronic Dis 2013;4:61-70. [PMID: 23556125 DOI: 10.1177/2040622312471840] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
130 Tincati C, Mondatore D, Bai F, d'Arminio Monforte A, Marchetti G. Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles? Open Forum Infect Dis 2020;7:ofaa340. [PMID: 33005694 DOI: 10.1093/ofid/ofaa340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, Felizarta F, Hao R, Ross L, Stancil B, Pappa K, Ha B; SUPPORT Study Team. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis 2013;13:269. [PMID: 23741991 DOI: 10.1186/1471-2334-13-269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
132 Portilla J, Moreno-Pérez O, Serna-Candel C, Escoín C, Alfayate R, Reus S, Merino E, Boix V, Giner L, Sánchez-Payá J, Picó A. Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV. J Int AIDS Soc 2014;17:18945. [PMID: 24836607 DOI: 10.7448/IAS.17.1.18945] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
133 Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, Steinhart C. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther 2018;7:183-95. [PMID: 29761330 DOI: 10.1007/s40121-018-0201-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
134 Dorjee K, Desai M, Choden T, Baxi SM, Hubbard AE, Reingold AL. Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States. AIDS Res Ther 2021;18:57. [PMID: 34488812 DOI: 10.1186/s12981-021-00383-7] [Reference Citation Analysis]
135 Schneider S, Spinner CD, Cassese S, Promny D, Hapfelmeier A, Byrne RA, Baumann M, Jäger H, Steinlechner E, Laugwitz KL, Kastrati A. Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. AIDS 2016;30:1413-21. [PMID: 26891035 DOI: 10.1097/QAD.0000000000001063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
136 Neesgaard B, Greenberg L, Miró JM, Grabmeier-pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-matthews A, Mussini C, Castagna A, Pradier C, d'Arminio Monforte A, Vehreschild JJ, Sönnerborg A, Anne AV, Carr A, Bansi-matharu L, Lundgren JD, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Necsoi C, van der Valk M, Menozzi M, Muccini C, Peters L, Mocroft A, Ryom L. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. The Lancet HIV 2022. [DOI: 10.1016/s2352-3018(22)00094-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR Jr, Hughes SH. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. Viruses 2021;13:205. [PMID: 33572956 DOI: 10.3390/v13020205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Derache A, Iwuji CC, Danaviah S, Giandhari J, Marcelin AG, Calvez V, de Oliveira T, Dabis F, Pillay D, Gupta RK. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. J Antimicrob Chemother 2019;74:473-9. [PMID: 30380053 DOI: 10.1093/jac/dky428] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
139 Pontrelli G, Martino AM, Tchidjou HK, Citton R, Mora N, Ravà L, Tozzi AE, Palma P, Muraca M, Franco E, Rossi P, Bernardi S. HIV is associated with thrombophilia and high D-dimer in children and adolescents. AIDS 2010;24:1145-51. [PMID: 20168205 DOI: 10.1097/QAD.0b013e328337b9a0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
140 Wang D, Melancon JK, Verbesey J, Hu H, Liu C, Aslam S, Young M, Wilcox CS. Microvascular Endothelial Dysfunction and Enhanced Thromboxane and Endothelial Contractility in Patients with HIV. J AIDS Clin Res 2013;4:267. [PMID: 24967147 DOI: 10.4172/2155-6113.1000267] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
141 Sandler NG, Sereti I. Can early therapy reduce inflammation? Curr Opin HIV AIDS 2014;9:72-9. [PMID: 24247669 DOI: 10.1097/COH.0000000000000020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
142 Loelius SG, Lannan KL, Blumberg N, Phipps RP, Spinelli SL. The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro. Thromb Res 2018;169:96-104. [PMID: 30031293 DOI: 10.1016/j.thromres.2018.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
143 Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, de Graeff PA, Mol PG. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports. Drug Saf 2011;34:1101-14. [PMID: 21981437 DOI: 10.2165/11592060-000000000-00000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
144 Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017;4:e349-56. [PMID: 28501495 DOI: 10.1016/S2352-3018(17)30066-8] [Cited by in Crossref: 428] [Cited by in F6Publishing: 235] [Article Influence: 85.6] [Reference Citation Analysis]
145 Kim J, Bang JH, Shin JY, Yang BR, Lee J, Park BJ. Hypertension Risk with Abacavir Use among HIV-Infected Individuals: A Nationwide Cohort Study. Yonsei Med J 2018;59:1245-52. [PMID: 30450860 DOI: 10.3349/ymj.2018.59.10.1245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
146 Sprenger HG, Bierman WF, Martes MI, Graaff R, van der Werf TS, Smit AJ. Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events. AIDS 2017;31:241-6. [PMID: 27763891 DOI: 10.1097/QAD.0000000000001297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
147 Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010;87:589-98. [PMID: 19952353 DOI: 10.1189/jlb.0809580] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 7.5] [Reference Citation Analysis]
148 Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther 2014;19:141-7. [PMID: 23985706 DOI: 10.3851/IMP2681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
149 Baker JV, Henry WK, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS 2009;4:176-82. [PMID: 19532047 DOI: 10.1097/COH.0b013e328329c62f] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
150 Martin A, Amin J, Emery S, Baker D, Carr A, Cooper DA, Bloch M; STEAL Study Group. Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One 2011;6:e26885. [PMID: 22046394 DOI: 10.1371/journal.pone.0026885] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
151 McCormick CL, Francis AM, Iliffe K, Webb H, Douch CJ, Pakianathan M, Macallan DC. Increasing Obesity in Treated Female HIV Patients from Sub-Saharan Africa: Potential Causes and Possible Targets for Intervention. Front Immunol 2014;5:507. [PMID: 25431572 DOI: 10.3389/fimmu.2014.00507] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
152 Husain NE, Ahmed MH. Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV AIDS (Auckl) 2015;7:1-10. [PMID: 25565897 DOI: 10.2147/HIV.S46028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
153 Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, Aandahl EM, Sandset PM, Taskén K, Kvale D. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol 2011;85:6557-66. [PMID: 21490090 DOI: 10.1128/JVI.00073-11] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
154 Di Biagio A, Lorenzini P, Gustinetti G, Rusconi S, De Luca A, Lapadula G, Lo Caputo S, Cicalini S, Castelli F, Marchetti G, Antinori A, Monforte AD. Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. AIDS Patient Care STDS 2017;31:487-94. [PMID: 29211512 DOI: 10.1089/apc.2017.0140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
155 Pett SL, Kelleher AD, Emery S. Role of interleukin-2 in patients with HIV infection. Drugs 2010;70:1115-30. [PMID: 20518579 DOI: 10.2165/10898620-000000000-00000] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
156 Mazzotta E, Agostinone A, Rosso R, Di Biagio A, De Socio GV, Cappelletti A, Zicolella R, Polilli E, Bonfanti P, Di Matteo L, Manzoli L, Parruti G. Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study. J Bone Miner Metab 2011;29:383-8. [PMID: 21258827 DOI: 10.1007/s00774-010-0245-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
157 Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT; ACTG A5001/ALLRT Protocol Team. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011;52:929-40. [PMID: 21427402 DOI: 10.1093/cid/ciq244] [Cited by in Crossref: 107] [Cited by in F6Publishing: 98] [Article Influence: 9.7] [Reference Citation Analysis]
158 Anuurad E, Semrad A, Berglund L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009;7:401-10. [PMID: 19355810 DOI: 10.1089/met.2008.0096] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
159 McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Sax PE. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012;26:1371-85. [PMID: 22546988 DOI: 10.1097/QAD.0b013e328354f4fb] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
160 Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M, Niero F, Biasin M, Bonfanti P, Ricci ED, Trabattoni D, Clerici M. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS 2013;27:381-9. [PMID: 23079800 DOI: 10.1097/QAD.0b013e32835abcc9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
161 Bahrami H, Budoff M, Haberlen SA, Rezaeian P, Ketlogetswe K, Tracy R, Palella F, Witt MD, McConnell MV, Kingsley L, Post WS. Inflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study. J Am Heart Assoc 2016;5:e003371. [PMID: 27353609 DOI: 10.1161/JAHA.116.003371] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
162 Vinaixa C, Herreras J, Blanes M, Maupoey J, Berenguer M, Prieto M, Aguilera V. Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk? Journal of Liver Transplantation 2021;1:100005. [DOI: 10.1016/j.liver.2021.100005] [Reference Citation Analysis]
163 Sico JJ, Chang CC, So-Armah K, Justice AC, Hylek E, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Bidwell Goetz M, Butt AA, Rodriguez-Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Freiberg MS; Veterans Aging Cohort Study. HIV status and the risk of ischemic stroke among men. Neurology 2015;84:1933-40. [PMID: 25862803 DOI: 10.1212/WNL.0000000000001560] [Cited by in Crossref: 119] [Cited by in F6Publishing: 78] [Article Influence: 17.0] [Reference Citation Analysis]
164 Go AS, Reynolds K, Avula HR, Towner WJ, Hechter RC, Horberg MA, Vupputuri S, Leong TK, Leyden WA, Harrison TN, Lee KK, Sung SH, Silverberg MJ. Human Immunodeficiency Virus Infection and Variation in Heart Failure Risk by Age, Sex, and Ethnicity: The HIV HEART Study. Mayo Clin Proc 2021:S0025-6196(21)00775-8. [PMID: 34916054 DOI: 10.1016/j.mayocp.2021.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
165 So-Armah K, Freiberg MS. Cardiovascular disease risk in an aging HIV population: not just a question of biology. Curr Opin HIV AIDS 2014;9:346-54. [PMID: 24824885 DOI: 10.1097/COH.0000000000000065] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
166 Odueyungbo A, Smieja M, Thabane L, Smaill F, Gough K, Gill J, Anderson T, Elston D, Smith S, Beyene J, Lonn E. Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study. AIDS Res Ther 2009;6:11. [PMID: 19519884 DOI: 10.1186/1742-6405-6-11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
167 Maloberti A, Dozio D, Betelli M, Bandera A, Squillace N, Gori A, Castoldi G, Stella A, Mancia G, Giannattasio C. Brachial and central blood pressure in HIV-infected subjects. Hypertens Res 2015;38:405-12. [PMID: 25740293 DOI: 10.1038/hr.2015.25] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
168 Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011;25:1289-98. [PMID: 21516027 DOI: 10.1097/QAD.0b013e328347fa16] [Cited by in Crossref: 111] [Cited by in F6Publishing: 62] [Article Influence: 10.1] [Reference Citation Analysis]
169 Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170:244-56. [PMID: 19494242 DOI: 10.1093/aje/kwp107] [Cited by in Crossref: 725] [Cited by in F6Publishing: 677] [Article Influence: 55.8] [Reference Citation Analysis]
170 Kebodeaux CD, Wilson AG, Smith DL, Vouri SM. A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV. HIV AIDS (Auckl) 2013;5:263-74. [PMID: 24068878 DOI: 10.2147/HIV.S36311] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
171 Poveda E, Soriano V. Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc. HIV AIDS (Auckl) 2010;2:51-8. [PMID: 22096384 DOI: 10.2147/hiv.s4977] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Crane HM, Heckbert SR, Drozd DR, Budoff MJ, Delaney JA, Rodriguez C, Paramsothy P, Lober WB, Burkholder G, Willig JH, Mugavero MJ, Mathews WC, Crane PK, Moore RD, Napravnik S, Eron JJ, Hunt P, Geng E, Hsue P, Barnes GS, McReynolds J, Peter I, Grunfeld C, Saag MS, Kitahata MM; Centers for AIDS Research Network of Integrated Clinical Systems Cohort Investigators. Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. Am J Epidemiol 2014;179:996-1005. [PMID: 24618065 DOI: 10.1093/aje/kwu010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
173 Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011;6:266-71. [PMID: 21546831 DOI: 10.1097/COH.0b013e328347876c] [Cited by in Crossref: 68] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
174 Oppenheim H, Paolillo EW, Moore RC, Ellis RJ, Letendre SL, Jeste DV, Grant I, Moore DJ; HIV Neurobehavioral Research Program (HNRP). Neurocognitive functioning predicts frailty index in HIV. Neurology 2018;91:e162-70. [PMID: 29875216 DOI: 10.1212/WNL.0000000000005761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
175 De Pablo C, Orden S, Apostolova N, Blanquer A, Esplugues JV, Alvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. AIDS 2010;24:1259-66. [PMID: 20453628 DOI: 10.1097/QAD.0b013e32833a2b02] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
176 Nan C, Shaefer M, Urbaityte R, Oyee J, Hopking J, Ragone L, Perger T, Win B, Vangerow H, McCoig C, Vannappagari V. Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials. Open Forum Infect Dis 2018;5:ofy086. [PMID: 29766019 DOI: 10.1093/ofid/ofy086] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
177 Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV. Curr HIV/AIDS Rep 2017;14:93-100. [PMID: 28434169 DOI: 10.1007/s11904-017-0356-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 18.4] [Reference Citation Analysis]
178 Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010;376:367-87. [PMID: 20650518 DOI: 10.1016/S0140-6736(10)60829-X] [Cited by in Crossref: 337] [Cited by in F6Publishing: 230] [Article Influence: 28.1] [Reference Citation Analysis]
179 Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009;23:1059-67. [PMID: 19390417 DOI: 10.1097/QAD.0b013e32832b514b] [Cited by in Crossref: 278] [Cited by in F6Publishing: 173] [Article Influence: 21.4] [Reference Citation Analysis]
180 Funderburg NT. Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS 2014;9:80-6. [PMID: 24275673 DOI: 10.1097/COH.0000000000000019] [Cited by in Crossref: 61] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
181 Patel P, Rose CE, Collins PY, Nuche-Berenguer B, Sahasrabuddhe VV, Peprah E, Vorkoper S, Pastakia SD, Rausch D, Levitt NS; NIH HIV/NCD Project Disease Condition Technical Operating Group. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. AIDS 2018;32 Suppl 1:S5-S20. [PMID: 29952786 DOI: 10.1097/QAD.0000000000001888] [Cited by in Crossref: 101] [Cited by in F6Publishing: 74] [Article Influence: 25.3] [Reference Citation Analysis]
182 Sinha A, Feinstein M. Epidemiology, pathophysiology, and prevention of heart failure in people with HIV. Prog Cardiovasc Dis 2020;63:134-41. [PMID: 31987806 DOI: 10.1016/j.pcad.2020.01.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
183 Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Sørensen HT, Gerstoft J. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6:e22698. [PMID: 21799935 DOI: 10.1371/journal.pone.0022698] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 9.2] [Reference Citation Analysis]
184 Karim R, Mack WJ, Kono N, Tien PC, Anastos K, Lazar J, Young M, Desai S, Golub ET, Kaplan RC, Hodis HN, Kovacs A. T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHS. J Acquir Immune Defic Syndr 2014;67:349-56. [PMID: 25314253 DOI: 10.1097/QAI.0000000000000311] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
185 George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010;24:387-94. [PMID: 20019575 DOI: 10.1097/QAD.0b013e3283359253] [Cited by in Crossref: 69] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
186 Nel J, Dlamini S, Meintjes G, Burton R, Black JM, Davies NECG, Hefer E, Maartens G, Mangena PM, Mathe MT, Moosa MY, Mulaudzi MB, Moorhouse M, Nash J, Nkonyane TC, Preiser W, Rassool MS, Stead D, van der Plas H, van Vuuren C, Venter WDF, Woods JF. Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. South Afr J HIV Med 2020;21:1115. [PMID: 33101723 DOI: 10.4102/sajhivmed.v21i1.1115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
187 Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, D'Agostino RB Sr. Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. Circulation 2018;137:2203-14. [PMID: 29444987 DOI: 10.1161/CIRCULATIONAHA.117.028975] [Cited by in Crossref: 93] [Cited by in F6Publishing: 42] [Article Influence: 23.3] [Reference Citation Analysis]
188 Calza L, Manfredi R, Colangeli V, Pocaterra D, Rosseti N, Pavoni M, Chiodo F. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS 2009;23:691-7. [PMID: 19739937 DOI: 10.1089/apc.2009.0039] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
189 Galindo J, Amariles P, Mueses-Marín HF, Hincapié JA, González-Avendaño S, Galindo-Orrego X. Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012. BMC Infect Dis 2016;16:532. [PMID: 27716093 DOI: 10.1186/s12879-016-1871-x] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
190 Hatleberg CI, Ryom L, El-Sadr W, Smith C, Weber R, Reiss P, Fontas E, Dabis F, Law M, Monforte Ad, De Wit S, Mocroft A, Phillips A, Lundgren JD, Sabin C; D:A:D Study Group. Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. AIDS 2016;30:1583-96. [PMID: 26950315 DOI: 10.1097/QAD.0000000000001076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
191 Dubé MP, Shen C, Mather KJ, Waltz J, Greenwald M, Gupta SK. Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retroviruses 2010;26:847-54. [PMID: 20673142 DOI: 10.1089/aid.2010.0007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
192 Shahmanesh M, Phillips K, Boothby M, Tomlinson JW. Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study. PLoS One 2015;10:e0117164. [PMID: 25617630 DOI: 10.1371/journal.pone.0117164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
193 Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, Delpech V, Phillips AN. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012;26:335-43. [PMID: 22089374 DOI: 10.1097/QAD.0b013e32834dcec9] [Cited by in Crossref: 293] [Cited by in F6Publishing: 176] [Article Influence: 29.3] [Reference Citation Analysis]
194 Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013;173:614-22. [PMID: 23459863 DOI: 10.1001/jamainternmed.2013.3728] [Cited by in Crossref: 738] [Cited by in F6Publishing: 732] [Article Influence: 82.0] [Reference Citation Analysis]
195 Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 2010;17:72-82. [PMID: 20005491 DOI: 10.1053/j.ackd.2009.07.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
196 Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents 2018;52:541-53. [PMID: 30040992 DOI: 10.1016/j.ijantimicag.2018.07.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
197 Siedner MJ. START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection. Open Forum Infect Dis 2016;3:ofw032. [PMID: 26989755 DOI: 10.1093/ofid/ofw032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
198 Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, Holodniy M, Barnett P, Owens DK. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis 2015;61:445-52. [PMID: 25908684 DOI: 10.1093/cid/civ316] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
199 Achenbach CJ, Scarsi KK, Murphy RL. Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. Adv Ther 2010;27:1-16. [PMID: 20204580 DOI: 10.1007/s12325-010-0006-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
200 Behrens GM. Abacavir and myocardial infarctions: the benefit of doubt? AIDS 2011;25:2043-5. [PMID: 21997489 DOI: 10.1097/QAD.0b013e32834bab9e] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
201 Burrowes S, Cahill P, Kottilil S, Bagchi S. Contribution of antiretroviral therapy to cardiovascular disease risk in HIV-infected patients. Future Virology 2016;11:509-27. [DOI: 10.2217/fvl-2016-0047] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
202 Enkhmaa B, Anuurad E, Zhang W, Li CS, Kaplan R, Lazar J, Merenstein D, Karim R, Aouizerat B, Cohen M, Butler K, Pahwa S, Ofotokun I, Adimora AA, Golub E, Berglund L. Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study. J Lipid Res 2018;59:1967-76. [PMID: 30012717 DOI: 10.1194/jlr.P084517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
203 Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, Xie Y, Martin JN, Ganz P, Deeks SG. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009;23:2021-7. [PMID: 19542863 DOI: 10.1097/QAD.0b013e32832e7140] [Cited by in Crossref: 117] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
204 Koethe JR, Grome H, Jenkins CA, Kalams SA, Sterling TR. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. AIDS 2016;30:83-91. [PMID: 26418084 DOI: 10.1097/QAD.0000000000000893] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
205 Chen R, Scherzer R, Hsue PY, Jotwani V, Estrella MM, Horberg MA, Grunfeld C, Shlipak MG. Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. J Am Heart Assoc 2017;6:e005387. [PMID: 28438737 DOI: 10.1161/JAHA.116.005387] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
206 Brouwer ES, Napravnik S, Eron JJ Jr, Stalzer B, Floris-Moore M, Simpson RJ Jr, Stürmer T. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology 2014;25:406-17. [PMID: 24713880 DOI: 10.1097/EDE.0000000000000041] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
207 Stein JH, Kime N, Korcarz CE, Ribaudo H, Currier JS, Delaney JC. Effects of HIV Infection on Arterial Endothelial Function: Results From a Large Pooled Cohort Analysis. Arterioscler Thromb Vasc Biol 2021;41:512-22. [PMID: 33327750 DOI: 10.1161/ATVBAHA.120.315435] [Reference Citation Analysis]
208 Calcagno A, Nozza S, Muss C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Ageing with HIV: a multidisciplinary review. Infection 2015;43:509-22. [PMID: 25987480 DOI: 10.1007/s15010-015-0795-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
209 Kaplan RC, Hanna DB, Kizer JR. Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults. Curr HIV/AIDS Rep 2016;13:44-52. [PMID: 26910597 DOI: 10.1007/s11904-016-0301-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
210 Martínez E, Larrousse M, Podzamczer D, Pérez I, Gutiérrez F, Loncá M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM; BICOMBO Study Team. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010;24:F1-9. [PMID: 20009917 DOI: 10.1097/QAD.0b013e32833562c5] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
211 Cruciani M, Malena M. Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations. Patient Prefer Adherence 2015;9:299-310. [PMID: 25733823 DOI: 10.2147/PPA.S65199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
212 Bedimo RJ, Drechsler H, Jain M, Cutrell J, Zhang S, Li X, Farukhi I, Castanon R, Tebas P, Maalouf NM. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS One 2014;9:e106221. [PMID: 25170938 DOI: 10.1371/journal.pone.0106221] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
213 Triant VA, Grinspoon SK. Epidemiology of ischemic heart disease in HIV. Curr Opin HIV AIDS 2017;12:540-7. [PMID: 28799997 DOI: 10.1097/COH.0000000000000410] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
214 Li RW, Yang C, Chan SW, Hoi MP, Lee SM, Kwan YW, Leung GP. Relaxation effect of abacavir on rat basilar arteries. PLoS One 2015;10:e0123043. [PMID: 25853881 DOI: 10.1371/journal.pone.0123043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
215 Serraino D, Bruzzone S, Zucchetto A, Suligoi B, De Paoli A, Pennazza S, Camoni L, Dal Maso L, De Paoli P, Rezza G. Elevated risks of death for diabetes mellitus and cardiovascular diseases in Italian AIDS cases. AIDS Res Ther 2010;7:11. [PMID: 20497520 DOI: 10.1186/1742-6405-7-11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
216 Baril JG, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, Walmsley S. Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. PLoS One 2016;11:e0148231. [PMID: 26849060 DOI: 10.1371/journal.pone.0148231] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
217 Jong E, Louw S, Meijers JC, de Kruif MD, ten Cate H, Büller HR, Mulder JW, van Gorp EC. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009;23:1001-7. [PMID: 19929230 DOI: 10.1089/apc.2009.0173] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
218 Padilla S, Masiá M, García N, Jarrin I, Tormo C, Gutiérrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011;11:40. [PMID: 21294867 DOI: 10.1186/1471-2334-11-40] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
219 Esplugues JV, De Pablo C, Collado-Díaz V, Hernández C, Orden S, Álvarez Á. Interference with purinergic signalling: an explanation for the cardiovascular effect of abacavir? AIDS 2016;30:1341-51. [PMID: 26990628 DOI: 10.1097/QAD.0000000000001088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
220 Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group. Abacavir use and risk of recurrent myocardial infarction. AIDS 2018;32:79-88. [PMID: 29028664 DOI: 10.1097/QAD.0000000000001666] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
221 Wever Pinzon O, Silva Enciso J, Romero J, Makani H, Fefer J, Gandhi V, Bangalore S, Chaudhry FA. Risk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography. Circ Cardiovasc Imaging 2011;4:363-70. [PMID: 21750273 DOI: 10.1161/CIRCIMAGING.110.961060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
222 Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am 2014;28:371-402. [PMID: 25151562 DOI: 10.1016/j.idc.2014.06.001] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 12.6] [Reference Citation Analysis]
223 Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M; Working Group 2. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118:e29-35. [PMID: 18566319 DOI: 10.1161/CIRCULATIONAHA.107.189624] [Cited by in Crossref: 233] [Cited by in F6Publishing: 133] [Article Influence: 16.6] [Reference Citation Analysis]
224 Lee GQ, McCluskey S, Boum Y 2nd, Hunt PW, Martin JN, Bangsberg DR, Gao X, Harrigan PR, Haberer JE, Siedner MJ. Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa? J Acquir Immune Defic Syndr 2017;76:188-92. [PMID: 28639996 DOI: 10.1097/QAI.0000000000001487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Capili B, Anastasi JK, Chang M, Ogedegbe O. Barriers and facilitators to engagement in lifestyle interventions among individuals with HIV. J Assoc Nurses AIDS Care 2014;25:450-7. [PMID: 24630628 DOI: 10.1016/j.jana.2014.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
226 Gupta SK, Shen C, Moe SM, Kamendulis LM, Goldman M, Dubé MP. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One 2012;7:e45716. [PMID: 23029197 DOI: 10.1371/journal.pone.0045716] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
227 Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis 2017;17:551. [PMID: 28793863 DOI: 10.1186/s12879-017-2626-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
228 Ho JE, Scherzer R, Hecht FM, Maka K, Selby V, Martin JN, Ganz P, Deeks SG, Hsue PY. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS 2012;26:1115-20. [PMID: 22382147 DOI: 10.1097/QAD.0b013e328352ce54] [Cited by in Crossref: 60] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
229 Schuster C, Binder C, Strassl R, Aichelburg MC, Blackwell E, Pavo N, Ramharter M, Hülsmann M, Grabmeier-Pfistershammer K, Rieger A, Goliasch G. Impact of HIV infection and antiretroviral treatment on N-terminal prohormone of brain natriuretic peptide as surrogate of myocardial function. AIDS 2017;31:395-400. [PMID: 28081038 DOI: 10.1097/QAD.0000000000001350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
230 Hileman CO, McComsey GA. The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV. Curr HIV/AIDS Rep 2019;16:381-8. [PMID: 31473903 DOI: 10.1007/s11904-019-00463-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
231 Rai MA, Pannek S, Fichtenbaum CJ. Emerging reverse transcriptase inhibitors for HIV-1 infection. Expert Opin Emerg Drugs 2018;23:149-57. [PMID: 29737220 DOI: 10.1080/14728214.2018.1474202] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
232 Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD; EuroSIDA study in EuroCOORD. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS 2013;27:907-18. [PMID: 23698060 DOI: 10.1097/QAD.0b013e32835cb766] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
233 Jiang B, Khandelwal AR, Rogers LK, Hebert VY, Kleinedler JJ, Zavecz JH, Shi W, Orr AW, Dugas TR. Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. Toxicol Sci 2010;117:524-36. [PMID: 20621964 DOI: 10.1093/toxsci/kfq213] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
234 Morillo-verdugo R, Robustillo-cortes MDLA, Navarro-ruiz A, Sánchez-rubio Ferrandez J, Fernández Espínola S, Fernández-pacheco García-valdecasas M, Vélez-díaz-pallarés M. Clinical Impact of the Capacity-Motivation-Opportunity Pharmacist-Led Intervention in People Living with HIV in Spain, 2019–2020. JMDH 2022;Volume 15:1203-11. [DOI: 10.2147/jmdh.s361305] [Reference Citation Analysis]
235 Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein JH; SABAR Study Team. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 2010;24:885-90. [PMID: 19952712 DOI: 10.1097/QAD.0b013e3283352ed5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
236 Adetokunboh OO, Schoonees A, Wiysonge CS. Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol. Syst Rev 2014;3:87. [PMID: 25115243 DOI: 10.1186/2046-4053-3-87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
237 Ekrikpo UE, Akpan EE, Ekott JU, Bello AK, Okpechi IG, Kengne AP. Prevalence and correlates of traditional risk factors for cardiovascular disease in a Nigerian ART-naive HIV population: a cross-sectional study. BMJ Open 2018;8:e019664. [PMID: 30030310 DOI: 10.1136/bmjopen-2017-019664] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
238 Vispo E, Moreno A, Maida I, Barreiro P, Cuevas A, Albertos S, Soriano V. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010;24:1171-6. [PMID: 20299955 DOI: 10.1097/QAD.0b013e3283389e26] [Cited by in Crossref: 70] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
239 Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases 2017; 5(2): 40-45 [PMID: 28255546 DOI: 10.12998/wjcc.v5.i2.40] [Reference Citation Analysis]
240 Boyd SD. Management of HIV infection in treatment-naive patients: a review of the most current recommendations. Am J Health Syst Pharm 2011;68:991-1001. [PMID: 21593227 DOI: 10.2146/ajhp100156] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
241 Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC;  HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96-138. [PMID: 25234519 DOI: 10.1093/cid/ciu617] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 21.6] [Reference Citation Analysis]
242 Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 2010;24:789-802. [PMID: 20224307 DOI: 10.1097/QAD.0b013e328337afdf] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
243 Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, Koethe JR, Arnett DK, Kabagambe EK. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis 2013;12:50. [PMID: 23575345 DOI: 10.1186/1476-511X-12-50] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
244 Taylor KA, Smyth E, Rauzi F, Cerrone M, Khawaja AA, Gazzard B, Nelson M, Boffito M, Emerson M. Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk. Br J Pharmacol 2019;176:879-89. [PMID: 30681136 DOI: 10.1111/bph.14589] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
245 Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA; INSIGHT ESPRIT & SILCAAT study groups. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010;24:1877-86. [PMID: 20588170 DOI: 10.1097/QAD.0b013e32833b1b26] [Cited by in Crossref: 62] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
246 Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 2011;214:468-73. [PMID: 21130995 DOI: 10.1016/j.atherosclerosis.2010.11.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
247 Fichtenbaum CJ. Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Curr HIV/AIDS Rep 2010;7:92-8. [PMID: 20425563 DOI: 10.1007/s11904-010-0045-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
248 Fitch K, Grinspoon S. Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. Am J Clin Nutr 2011;94:1721S-8S. [PMID: 22089442 DOI: 10.3945/ajcn.111.012120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
249 Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr 2017;74:180-4. [PMID: 27673443 DOI: 10.1097/QAI.0000000000001186] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 8.6] [Reference Citation Analysis]
250 Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010;15:1077-86. [PMID: 21149914 DOI: 10.3851/IMP1681] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
251 Naidu ECS, Olojede SO, Lawal SK, Rennie CO, Azu OO. Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology. Pharmacol Res Perspect 2021;9:e00776. [PMID: 34107163 DOI: 10.1002/prp2.776] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
252 Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am 2009;38:207-22. [PMID: 19217520 DOI: 10.1016/j.ecl.2008.11.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
253 Srisawasdi P, Suwalak T, Sukasem C, Chittamma A, Pocathikorn A, Vanavanan S, Puangpetch A, Santon S, Chantratita W, Kiertiburanakul S, Kroll MH. Small-dense LDL cholesterol/large-buoyant LDL cholesterol ratio as an excellent marker for indicating lipodystrophy in HIV-infected patients. Am J Clin Pathol 2013;140:506-15. [PMID: 24045547 DOI: 10.1309/AJCPE5I3KELTBXEJ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
254 Lee FJ, Amin J, Carr A. Limited reporting of major harms in studies of initial combination antiretroviral therapy: a systematic review. AIDS 2015;29:921-9. [PMID: 25784442 DOI: 10.1097/QAD.0000000000000633] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
255 Potthoff A, Rasokat H, Brockmeyer NH. [HIV infection]. Hautarzt 2012;63:10-5. [PMID: 22212157 DOI: 10.1007/s00105-011-2195-9] [Reference Citation Analysis]
256 Maggi P, Quirino T, Ricci E, De Socio GV, Gadaleta A, Ingrassia F, Perilli F, Lillo A, Bonfanti P. Cardiovascular risk assessment in antiretroviral-naïve HIV patients. AIDS Patient Care STDS 2009;23:809-13. [PMID: 19824809 DOI: 10.1089/apc.2009.0102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
257 Rider OJ, Asaad M, Ntusi N, Wainwright E, Clutton G, Hancock G, Banerjee R, Pitcher A, Samaras K, Clarke K, Neubauer S, Dorrell L, Holloway CJ. HIV is an independent predictor of aortic stiffness. J Cardiovasc Magn Reson 2014;16:57. [PMID: 25187084 DOI: 10.1186/s12968-014-0057-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
258 Baker JV, Henry WK, Patel P, Bush TJ, Conley LJ, Mack WJ, Overton ET, Budoff M, Hammer J, Carpenter CC, Hodis HN, Brooks JT; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy Investigators. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis 2011;53:826-35. [PMID: 21860012 DOI: 10.1093/cid/cir497] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
259 Gerver SM, Chadborn TR, Ibrahim F, Vatsa B, Delpech VC, Easterbrook PJ. High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort. J Int AIDS Soc 2010;13:29. [PMID: 20684760 DOI: 10.1186/1758-2652-13-29] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
260 Hurwitz SJ, Schinazi RF. Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol 2012;9:e183-93. [PMID: 23554824 DOI: 10.1016/j.ddtec.2012.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
261 Schewe K, Noah C, Sirma H, Schmiedel S, van Lunzen J, Rockstroh JK, Schildgen O. Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report. Viruses 2010;2:1564-70. [PMID: 21994693 DOI: 10.3390/v2081564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
262 Pourcher V, Gourmelen J, Bureau I, Bouee S. Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France. PLoS One 2020;15:e0243529. [PMID: 33332394 DOI: 10.1371/journal.pone.0243529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
263 Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, Wood K, Holmberg SD, Brooks JT; HOPS Investigators. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis 2013;10:E10. [PMID: 23347705 DOI: 10.5888/pcd10.120083] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
264 Williams RJ, Tse T, Harlan WR, Zarin DA. Registration of observational studies: is it time? CMAJ 2010;182:1638-42. [PMID: 20643833 DOI: 10.1503/cmaj.092252] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
265 Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem Av, de Wolf F, Hallett TB. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810-818. [PMID: 26070969 DOI: 10.1016/s1473-3099(15)00056-0] [Cited by in Crossref: 357] [Cited by in F6Publishing: 188] [Article Influence: 51.0] [Reference Citation Analysis]
266 Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther 2009;14:165-79. [PMID: 19430091 DOI: 10.1177/135965350901400203] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
267 Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, Brainard DM, Martin H; GS-US-380–4030 Investigators. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis 2021;73:e485-93. [PMID: 32668455 DOI: 10.1093/cid/ciaa988] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
268 Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol 2019;16:745-59. [PMID: 31182833 DOI: 10.1038/s41569-019-0219-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
269 Duarte H, Matta JR, Muldoon N, Masur H, Hadigan C, Gharib AM. Non-calcified coronary plaque volume inversely related to CD4(+) T-cell count in HIV infection. Antivir Ther 2012;17:763-7. [PMID: 22293714 DOI: 10.3851/IMP1994] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
270 Rasmussen LD, Engsig FN, Christensen H, Gerstoft J, Kronborg G, Pedersen C, Obel N. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 2011;25:1637-46. [PMID: 21646903 DOI: 10.1097/QAD.0b013e3283493fb0] [Cited by in Crossref: 113] [Cited by in F6Publishing: 71] [Article Influence: 10.3] [Reference Citation Analysis]
271 Cahn P, Rolón MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc 2017;20:21678. [PMID: 28537061 DOI: 10.7448/IAS.20.01.21678] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 8.8] [Reference Citation Analysis]
272 Rodríguez-Arbolí E, Mwamelo K, Kalinjuma AV, Furrer H, Hatz C, Tanner M, Battegay M, Letang E; KIULARCO Study Group. Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study. PLoS One 2017;12:e0172089. [PMID: 28273105 DOI: 10.1371/journal.pone.0172089] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
273 Rasmussen LD, Omland LH, Pedersen C, Gerstoft J, Kronborg G, Jensen J, Obel N. Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study. BMC Infect Dis 2010;10:169. [PMID: 20546604 DOI: 10.1186/1471-2334-10-169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
274 Lichtenstein KA. Antiretroviral treatment interruptions and risk of non-opportunistic diseases. Curr HIV/AIDS Rep 2009;6:77-82. [PMID: 19358778 DOI: 10.1007/s11904-009-0012-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
275 Hanna DB, Moon JY, Haberlen SA, French AL, Palella FJ Jr, Gange SJ, Witt MD, Kassaye S, Lazar JM, Tien PC, Feinstein MJ, Kingsley LA, Post WS, Kaplan RC, Hodis HN, Anastos K. Carotid artery atherosclerosis is associated with mortality in HIV-positive women and men. AIDS 2018;32:2393-403. [PMID: 30102657 DOI: 10.1097/QAD.0000000000001972] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
276 Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, Manzini T, Mathe M, Moosa Y, Nash J, Nel J, Pakade Y, Woods J, Van Zyl G, Conradie F, Venter F. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med 2017;18:776. [PMID: 29568644 DOI: 10.4102/sajhivmed.v18i1.776] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 18.2] [Reference Citation Analysis]
277 Rosenblatt L, Farr AM, Johnston SS, Nkhoma ET. Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens. Open Forum Infect Dis 2016;3:ofw061. [PMID: 27186585 DOI: 10.1093/ofid/ofw061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
278 Schillaci G, Pucci G, De Socio GV. HIV infection and antiretroviral treatment: a "two-hit" model for arterial stiffness? Am J Hypertens 2009;22:817-8. [PMID: 19638954 DOI: 10.1038/ajh.2009.113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
279 Jabłonowska E, Siwak E, Bociąga-Jasik M, Gąsiorowski J, Kalinowska A, Firląg Burkacka E, Wójcik-Cichy K, Piątek A, Cielniak I, Horban A. Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. PLoS One 2019;14:e0210476. [PMID: 30653541 DOI: 10.1371/journal.pone.0210476] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
280 Triant VA, Siedner MJ. Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care. J Infect Dis 2020;221:498-500. [PMID: 31828327 DOI: 10.1093/infdis/jiz482] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
281 Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, Paltiel AD, Kelly KA, Seage GR 3rd, Walensky RP, Weinstein MC, Eron J, Freedberg KA. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One 2014;9:e113031. [PMID: 25397616 DOI: 10.1371/journal.pone.0113031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
282 Longenecker CT, Triant VA. Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS 2014;9:54-62. [PMID: 24275676 DOI: 10.1097/COH.0000000000000015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
283 Sellers CJ, Wohl DA. Antiretroviral therapy: when to start. Infect Dis Clin North Am 2014;28:403-20. [PMID: 25151563 DOI: 10.1016/j.idc.2014.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
284 Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M; D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med 2011;12:412-21. [PMID: 21251183 DOI: 10.1111/j.1468-1293.2010.00901.x] [Cited by in Crossref: 128] [Cited by in F6Publishing: 119] [Article Influence: 11.6] [Reference Citation Analysis]
285 Capili B, Anastasi JK, Ogedegbe O. HIV and general cardiovascular risk. J Assoc Nurses AIDS Care 2011;22:362-75. [PMID: 21277230 DOI: 10.1016/j.jana.2010.12.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
286 Eyawo O, Brockman G, Goldsmith CH, Hull MW, Lear SA, Bennett M, Guillemi S, Franco-Villalobos C, Adam A, Mills EJ, Montaner JSG, Hogg RS. Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis. BMJ Open 2019;9:e025874. [PMID: 31551371 DOI: 10.1136/bmjopen-2018-025874] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
287 Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV infection and older Americans: the public health perspective. Am J Public Health 2012;102:1516-26. [PMID: 22698038 DOI: 10.2105/AJPH.2012.300844] [Cited by in Crossref: 128] [Cited by in F6Publishing: 67] [Article Influence: 12.8] [Reference Citation Analysis]
288 Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS; Aries EPZ108859 Study Team. Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses 2013;29:350-8. [PMID: 23039030 DOI: 10.1089/aid.2012.0278] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
289 Fuchs SC, Alencastro PR, Ikeda ML, Barcellos NT, Wolff FH, Brandão AB, Ximenes RA, Miranda-Filho Dde B, Lacerda HR, de Albuquerque Mde F, Montarroyos UR, Nery MW, Turchi MD. Risk of coronary heart disease among HIV-infected patients: a multicenter study in Brazil. ScientificWorldJournal 2013;2013:163418. [PMID: 24223499 DOI: 10.1155/2013/163418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
290 Ahmed MH, Woodward C, Mital D. Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services. Cardiovasc Endocrinol 2017;6:109-12. [PMID: 31646127 DOI: 10.1097/XCE.0000000000000128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
291 Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011;25:1993-2004. [PMID: 21716077 DOI: 10.1097/QAD.0b013e328349c6ee] [Cited by in Crossref: 113] [Cited by in F6Publishing: 59] [Article Influence: 10.3] [Reference Citation Analysis]
292 Goodwin SR, Reeds DN, Royal M, Struthers H, Laciny E, Yarasheski KE. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab. 2013;98:743-751. [PMID: 23264399 DOI: 10.1210/jc.2012-3532] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
293 Hulgan T, Boger MS, Liao DH, McComsey GA, Wanke CA, Mangili A, Walmsley SL, McCreath H, Milne GL, Sanchez SC, Currier JS, Lake JE. Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. Mediators Inflamm 2014;2014:803095. [PMID: 24991090 DOI: 10.1155/2014/803095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]